Treatment for the Cure of Type I Diabetes
Patent Numbers:
General Description:
Type I Diabetes (T1D) is an autoimmune disease caused by the destruction of the body’s insulin-producing pancreatic islet β-cells. T1D affects millions of Americans, with over 40,000 new diagnoses each year. Current treatments address the symptoms of the disease by supplementing insulin by injection; a treatment requiring constant management and multiple daily injections. Technology developed by Habib Zaghouani at the University of Missouri lays the foundation for a cure to the underlying cause of T1D, through reversal of the autoimmune response and subsequent recovery of the natural insulin-producing pancreatic islet β-cells.
Strengths:
Patent Status:
Inventor Bio: Habib Zaghouani
https://medicine.missouri.edu/faculty/habib-zaghouani-phd/
- US 14/773/497
- CN 201480022386.4
- CA 2,904,586
- EPC 14760521.6
- PCT/US2017/052849
- US 8,603,472
- US 8,609,091
- US 7,744,876
- US 8,603,471
- Invention Type: Therapeutic
- Patent Status: Active
- Representative Patent Link: https://patents.google.com/patent/US8603472B2/
- Research Institute: University of Missouri
- Disease Focus: Type I Diabetes
- Basis of Invention: Therapeutic protein + endothelial cell progenitors
- How it works: Type I Diabetes occurs when the immune system destroys the insulin-producing β-cells of the pancreatic islets. Administration of a chimeric Ig-GAD2 protein eliminates the self reactive T-cells responsible for destruction of the β-cells and allows recovery from pre-diabetic insulinitis and hyperglycemia. Co-administration of the Ig-GAD2 protein with endothelial cell progenitors enables full recovery from overt Type I Diabetes through restoration of the pancreatic islet β-cells as well as the surrounding endothelial cells.
- Lead Challenge Inventor: Habib Zaghouani
- Development Stage: Pre-clinical (mouse data)
- Novelty:
- Therapeutic Ig-GAD2 protein therapy alone or in conjunction with the administration of endothelial cell progenitors for the treatment of and full recovery from Type I Diabetes
- Clinical Applications:
- Application of this therapy can prevent or reverse Type I Diabetes
General Description:
Type I Diabetes (T1D) is an autoimmune disease caused by the destruction of the body’s insulin-producing pancreatic islet β-cells. T1D affects millions of Americans, with over 40,000 new diagnoses each year. Current treatments address the symptoms of the disease by supplementing insulin by injection; a treatment requiring constant management and multiple daily injections. Technology developed by Habib Zaghouani at the University of Missouri lays the foundation for a cure to the underlying cause of T1D, through reversal of the autoimmune response and subsequent recovery of the natural insulin-producing pancreatic islet β-cells.
Strengths:
- Ig-GAD2 treatment demonstrated in mouse models of T1D to prevent the onset of T1D through recovery of pancreatic islet β-cells through the pre-diabetic stages of insulinitis and hyperglycemia
- Ig-GAD2 treatment in conjunction with the administration of endothelial cell progenitors demonstrated as a functional cure to overt T1D in mouse models of T1D through recovery of pancreatic islet β-cells and their surrounding endothelial cells
Patent Status:
- Multiple issued and pending patents
Inventor Bio: Habib Zaghouani
https://medicine.missouri.edu/faculty/habib-zaghouani-phd/
